Applications Open for Bloodwise Early Phase Clinical Trial Grants

 

Bloodwise provides Early Phase Clinical Trial Grants to support early phase investigator-led interventional studies to evaluate new blood cancer treatments, with the aim of delivering trials which could translate into further studies to evaluate clinical efficacy. Applications are expected to be developed with the involvement of a relevant clinical trials unit. Up to £400,000 can be requested.

The types of studies that the scheme supports include:

  • Phase 1/Phase 2 trials to ascertain safety, side effects, best dose and preliminary efficacy of new therapies in humans or novel therapy combinations, which can include radiotherapy or novel indications for existing drugs.
  • Phase 1b/2 or Phase 2 trials testing the feasibility of larger trials, and/or to explore the tolerability, biological activity and effects of the intervention.
  • Studies of treatment approaches aiming to achieve equivalence of survival will be considered, if the possibility of reduced toxicity or optimisation of treatment delivery can be shown, along with the potential to substantially improve patient outcome.

Applications must be from a tenured academic, scientist or clinician from a UK university, research institution or clinical centre, and developed with the involvement of an experienced UK Clinical Research Collaboration-registered Clinical Trials Unit (CTU). The main applicant must have a salaried position for the duration of the grant.

The organisation hosting the research and administering the funds for a clinical trial or study must be a UK university, research institution or CTU.

Applications should be submitted by the deadline of 25 February 2020.

 

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.